Voormalige ceo van Novartis-Sandoz (Zuid-Afrika) aan het hoofd van AAT Research
SAN GWANN, Malta–(BUSINESS WIRE)– AAT Research, een onderzoeksfirma die kwalitatief hoogwaardige medische systemen ontwerpt en ontwikkelt, heeft vandaag bekendgemaakt dat het Wolfgang Storf, veteraan in de geneeskunde en farmacie, heeft benoemd tot zijn nieuwe ceo.
Voor zijn toetreding tot AAT, was Storf strategisch hoofd van de MS Pharma Group. Hij was ook ceo van Novartis-Sandoz in Zuid-Afrika en bekleedde andere functies bij Novartis-Sandoz, Apotex en Johnson & Johnson in verschillende delen van de wereld. Storf is een ervaren leidinggevende met bewezen internationale ervaring in strategisch en uitvoerend leiderschap, dat zich uitstrekt over commerciële operaties, technische activiteiten en verantwoordelijkheid voor onderzoek en ontwikkeling bij multinationale en niet-beursgenoteerde bedrijven. Hij heeft ook ervaring in integratieprogramma’s na fusies in markten met en zonder sterke merkposities.
Former CEO of Novartis-Sandoz (South Africa) to Lead AAT Research’s Global Expansion
SAN GWANN, Malta–(BUSINESS WIRE)– AAT Research, a research firm that designs and develops quality medical solutions in the neuroscience space, today announced that it has appointed pharmaceutical and medical industry veteran Wolfgang Storf as its new chief executive officer.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160406005565/en/
Wolfgang StorfMr Storf brings more than 20 years of experience in the industry with a successful record of entering new markets, providing strategic direction and boosting growth.
Prior to joining AAT, he was chief strategy officer with the MS Pharma Group. He was also CEO of Novartis-Sandoz in South Africa and held other senior management positions with Novartis-Sandoz, Apotex and Johnson & Johnson in different regions of the world. Mr Storf is a seasoned senior executive with proven global strategic and execution leadership experience – covering both commercial and technical operations as well R&D responsibility inside multinational and private businesses in the pharmaceutical and medical industry. He also has experience in post-merger integration programs in both branded / un-branded markets.
“I am delighted to take over as CEO at this important stage of AAT’s growth, and I’m looking forward to working with the executive team and the board to help the company realise its full potential, enter new markets and establish our products as leading therapies and services for patients and medical professionals respectively,” Mr Storf said.
AAT Research’s Founder and Chief Scientific Officer, Dr Adrian Attard Trevsisan, said: “We have come a long way from a small one-room setup. As the company continues to grow and increase its international footprint, we felt the need to bring in a senior executive who has extensive international experience in the pharmaceutical and medical industries.”
“The board of directors and I are extremely pleased that Wolfgang has joined the company and he will be a determining factor in the internationalisation of AAT in the coming months. I will be taking on the role of Chief Scientific Officer and Director of Product, focusing on research, innovation and product development,” Dr Attard Trevisan added.
-ends-
About AAT Research
The AAT Research group of companies researches, designs, develops and manufactures quality medical solutions. With regulatory and quality systems in place and various international accreditations to its name, the group aims to lead innovation in the neurosciences field. AAT’s purpose is to improve people’s lives though innovation in the field of neuroscience and medical technology and our mission is to develop quality medical devices and cloud-based services to help improve the lives of those with neurologically-based conditions such as autism, epilepsy, depression and anxiety. For more information visit: http://www.aatrl.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160406005565/en/
Contacts
Media contact:
AAT Research
David Kelleher
David.kelleher@aatrl.com
Tel: +356 21330588